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Derangements in serum phosphate level result in rickets/osteomalacia or ectopic calciﬁcation indicating that healthy people
withouttheseabnormalitiesmaintainserumphosphatewithincertainranges.Theseresultsindicatethattheremustbearegulatory
mechanism of serum phosphate level. Fibroblast growth factor 23 (FGF23) was identiﬁed as the last member of FGF family. FGF23
is produced by bone and reduces serum phosphate level by suppressing phosphate reabsorption in proximal tubules and intestinal
phosphate absorption through lowering 1,25-dihydroxyvitamin D level. It has been shown that excess and deﬁcient actions of
FGF23 result in hypophosphatemic rickets/osteomalacia and hyperphosphatemic tumoral calcinosis, respectively. These results
indicate that FGF23 works as a hormone, and several disorders of phosphate metabolism can be viewed as endocrine diseases.
It may become possible to treat patients with abnormal phosphate metabolism by pharmacologically modifying the activity of
FGF23.
Copyright © 2009 T. Saito and S. Fukumoto. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
It is well known that serum calcium (Ca) level is regu-
lated within a narrow range by actions of two calcium-
regulating hormones, parathyroid hormone (PTH) and
1,25-dihydroxyvitamin D [1,25(OH)2D]. In contrast, while
derangements in serum phosphate level result in rick-
ets/osteomalacia or ectopic calciﬁcation, the regulatory
mechanismsofserumphosphatehavebeenlargelyunknown.
Because PTH and 1,25(OH)2Dc a na ﬀect serum phosphate
level, it has been unclear whether there is a tight mechanism
of serum phosphate level regulated by a speciﬁc phosphate-
regulatinghormone.However,theidentiﬁcationofﬁbroblast
growth factor 23 (FGF23) and subsequent studies certainly
changed this view. FGF23 works as a phosphate-regulating
hormone and aberrant functions of FGF23 result in several
diseases. Here, we brieﬂy review the physiological and
pathophysiological roles of FGF23.
2. Structure and Function of FGF23
FGF family members are now deﬁned as humoral factor-
swhich have FGF homology region characterized by β-trefoil
structure. FGF23 was identiﬁed as the last member of FGF
family [1] and belongs to the FGF19 subfamily as well as
FGF19 and FGF21 [2]. FGF23 is produced as a peptide with
251 amino acids by bone [3, 4] .T h e r ei sas i gn a lpe p t i d ewi t h
24 amino acids, and the secreted FGF23 protein consists of
227 amino acids which is approximately 32-kD [5]. A part
of FGF23 protein is proteolytically cleaved between 179Arg
and 180Ser into inactive fragments by enzymes that recognize
176R-177X-178X-179R motif just before the processing site
(Figure 1). FGF homology region is present in the N-
terminal portion of this processing site of FGF23.
It has been shown that FGF23 suppresses the expression
of type 2a and 2c sodium-phosphate cotransporters in
the brush border membrane of proximal tubules which2 International Journal of Pediatric Endocrinology
mediate physiological phosphate reabsorption. In addition,
FGF23 reduces serum 1,25(OH)2D level by suppressing
the expression of 25-hydroxyvitamin D [25(OH)D]-1α-
hydroxylase and also enhancing the expression of 25(OH)D-
24-hydroxylase [6]. This 1α-hydroxylase mediates the pro-
duction of 1,25(OH)2D from 25(OH)D, and 24-hydroxylase
converts 1,25(OH)2D into more hydrophilic metabolites
with less activity. Because 1,25(OH)2D enhances intestinal
phosphate absorption, FGF23 reduces serum phosphate
level by its suppressive eﬀects on phosphate reabsorption
in proximal tubules and phosphate absorption in intestine
(Figure 2). Conversely, 1,25(OH)2D was shown to increase
FGF23 level and enhance promoter activity of FGF23 gene
[7].Ithasbeenalsoshownthathighphosphatedietincreases
circulatory FGF23 [8]. However, acute changes of serum
phosphatedonotalterFGF23levelsinhuman[9].Itremains
to be clariﬁed how changes in dietary phosphate modulate
FGF23 levels.
While it is well known that PTH also decreases serum
phosphate level by reducing the expression of type 2a and
2c sodium-phosphate cotransporters, eﬀects of FGF23 on
serum phosphate can be observed in thyroparathyroidec-
tomized rats [6]. Therefore, while both PTH and FGF23
reduce the expression of sodium-phosphate cotransporters,
FGF23 does not require PTH for its activity to reduce the
expression of sodium-phosphate cotransporters. Although
full-lengthFGF23caninducehypophosphatemia,cleavedN-
terminal and C-terminal fragments do not reduce serum
phosphatelevelwheninjectedintomice[10].Therefore,only
the full-length FGF23 has the biological activity to reduce
serum phosphate level.
3. FGF23and Klotho
FGF23 is produced by bone and acts on kidney indicating
that FGF23 is a systemic factor in contrast to many other
members of FGF family. It is well known that FGF family
members bind to FGF receptors (FGFRs). There are four
FGFR genes, and several FGFR subtypes are created form
these genes by alternative splicing. However, the aﬃnity of
FGF23 to these FGFRs is low [11] suggesting that some
other molecule(s) may be involved in FGF23 signaling.
Indeed, FGF23 was found to bind to Klotho, a cell surface
protein with homologies to β-glucosidases [11]. Klotho was
originally identiﬁed as a gene product whose expression is
severely reduced in transgenic mice named Klotho [12]. The
evidence for Klotho’s role in FGF23 action is as follows: (1)
Klotho is localized in kidney, parathyroid gland, pituitary,
and choroid plexus in the brain [13], the tissues where
the inductions of early growth response (Egr)-1 expres-
sion and phosphorylation of extracellular signal-regulated
kinase (ERK) were observed following FGF23 injections in
mice [11]; (2) FGF23-null and Klotho mice show similar
phenotypes such as hyperphosphatemia, inappropriately
high levels of 1,25(OH)2D in the presence of hyperphos-
phatemia, calciﬁcations of soft tissues, and short life span;
(3) anti-Klotho antibody increases serum phosphate and
1,25(OH)2D levels in wild-type mice [11]; (4) circulatory
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Figure 1: Structure FGF23 protein. FGF23 is produced as a peptide
with 251 amino acids. There is a signal peptide with 24 amino
acids, and the secreted FGF23 protein consists of 227 amino acids.
A part of FGF23 protein is proteolytically cleaved between 179Arg
and 180Ser into inactive fragments by enzymes that recognize 176R-
177X-178X-179R motif just before the processing site. FGF homology
region is present in the N-terminal portion of this processing site of
FGF23.
FGF23 level is extremely high in Klotho mice. Further
studies have shown that Klotho, FGF23, and FGFR1c make
a heterotrimer complex in vitro, and the binding of FGF23
to FGFR1c is enhanced by Klotho [11, 14]. Therefore,
Klotho appears to be necessary for FGF23 to decrease serum
phosphate and 1,25(OH)2D levels and is an indispensable
molecule for FGF23 signaling (Figure 3).
4.FGF23-RelatedDiseases
4.1. Hypophosphatemic Diseases. Rickets and osteomalacia
arecharacterizedbyimpaired mineralization ofbonematrix.
Rickets develops in children before the closure of growth
plate. Growth retardation and bone deformity are predom-
inant features of rickets while severe muscle weakness and
bone pain are usual symptoms of osteomalacia in adults.
There are many causes of rickets and osteomalacia such as
vitamin D deﬁciency, abnormal metabolism of vitamin D,
and renal tubular dysfunction (Table 1). Chronic hypophos-
phatemia is present in almost all cases of rickets and osteo-
malacia except for hypophosphatasia caused by mutations
in TNALP gene encoding tissue nonspeciﬁc alkaline phos-
phatase [15]. It has been known that there are several kinds
of hypophosphatemic rickets/osteomalacia with very similar
clinicalfeatures[16].Theseincludeautosomaldominantand
recessive hypophosphatemic rickets/osteomalacia (ADHR,
ARHR), X-linked hypophosphatemic rickets/osteomalacia
(XLH), hypophosphatemic rickets/osteomalacia associated
with McCune-Albright syndrome (MAS)/ﬁbrous dysplasia
(FD), and tumor-induced rickets/osteomalacia (TIO). These
diseases are characterized by impaired phosphate reabsorp-
tion in proximal tubules. In addition, hypophosphatemia
usually causes enhanced production of 1,25(OH)2Di nInternational Journal of Pediatric Endocrinology 3
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Figure 2: Actions of FGF23. FGF23 is produced by bone. FGF23
suppresses the expression of type 2a and 2c sodium-phosphate
cotransporters (NaPi) in the brush border membrane of proximal
tubules which mediate physiological phosphate reabsorption. In
addition, FGF23 reduces serum 1,25(OH)2D level by suppressing
theexpressionof25-hydroxyvitaminD[25(OH)D]-1α-hydroxylase
and also enhancing the expression of 25(OH)D-24-hydroxylase.
This 1α-hydroxylase mediates the production of 1,25(OH)2Df r o m
25(OH)D, and 24-hydroxylase converts 1,25(OH)2D into more
hydrophilic metabolites with less activity. Because 1,25(OH)2D
enhances intestinal phosphate absorption, FGF23 reduces serum
phosphate level by its suppressive eﬀects on renal phosphate
reabsorption and intestinal phosphate absorption. Conversely,
1,25(OH)2D increases FGF23 level. High phosphate diet also
increasescirculatoryFGF23.However,itremainstobeclariﬁedhow
changes in dietary phosphate modulate FGF23 level.
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Figure 3: Heterotrimer complex of Klotho, FGF23, and FGFR1c.
Klotho, FGF23, and FGFR1c make a heterotrimer complex in order
to transmit the signal of FGF23 to target organs. Therefore, Klotho
seemstobenecessaryforFGF23signaling.N:N-terminusofFGF23
protein; C: C-terminus of FGF23 protein.
proximal tubules and increases serum 1,25(OH)2Dl e v e l .
However, serum 1,25(OH)2D levels in these FGF23-related
hypophosphatemic rickets/osteomalacia remain low to low
normal. Therefore, it was presumed that not only impaired
proximal tubular phosphate reabsorption but also abnormal
metabolism of vitamin D underlie these hypophosphatemic
diseases. As easily expected from actions of FGF23, it
has been shown that FGF23 is closely related to these
hypophosphatemic diseases. In addition to these diseases, it
has been recently reported that infusion of saccharated ferric
oxide (iron polymaltose) can also lead to renal phosphate
wasting mediated by increased FGF23 [17–19].
4.2. ADHR. ADHR is a rare familial hypophosphatemic
rickets/osteomalaciawhichdoesnotrespondtophysiological
dose of native vitamin D. FGF23 was identiﬁed as a
responsible gene for ADHR by positional cloning in 2000
[20]. Three heterozygous missense mutations around the
processing site of FGF23 protein have been identiﬁed in
ADHR families. These mutations replace 176Arg or 179Arg in
FGF23 protein with other amino acids destroying R-X-X-R
motif. Therefore, it has been presumed that the cleavage of
FGF23 protein between 179Arg and 180Ser is prevented by
these mutations causing increased full-length FGF23 level.
However, the circulatory FGF23 levels in 42 ADHR patients
were not signiﬁcantly diﬀerent from those of controls [21].
On the other hand, FGF23 levels in ADHR patients ﬂuctuate
with time and are high when they show hypophosphatemia.
These results indicate that FGF23 levels are not always high
in patients with ADHR indicating that the resistance to
the processing of FGF23 protein alone does not explain
enhanced activity of FGF23 in these patients. We have previ-
ously shown that FGF23 levels are low in hypophosphatemic
patients caused by other etiologies than FGF23 excess
such as Fanconi syndrome and vitamin D deﬁciency [22].
Therefore, high FGF23 levels in the presence of hypophos-
phatemia in patients with ADHR rather suggest that the
regulatory mechanisms of FGF23 production are somehow
deranged in these patients. Further studies are necessary
to clarify the pathogenesis of hypophosphatemia in ADHR
patients.
4.3. ARHR. ARHR is also a rare familial hypophosphatemic
rickets/osteomalacia which shows resistance to native vita-
min D like ADHR. Almost all cases are observed in fam-
ilies with consanguineous marriage. Dentin matrix protein
(DMP)1 was identiﬁed as a responsible gene for ARHR by
positional cloning in 2006, and several homozygous muta-
tions in DMP1 gene were identiﬁed in patients with ARHR
[23, 24]. DMP1 is a matrix protein found in osteocytes
and odontoblasts and belongs to a family of small integrin-
binding ligand, N-linked glycoproteins (SIBLING) together
with matrix proteins in calciﬁed tissues such as dentin
sialophosphoprotein (DSPP), integrin-binding sialoprotein
(IBSP), matrix extracellular phosphoglycoprotein (MEPE),
and osteopontin. It is reported that homozygous DMP1
knock-out mice show features of hypophosphatemic rickets,
and serum FGF23 levels of DMP1 knock-out mice and
ARHR patients are high [23, 24]. In addition, FGF23
was shown to be abundantly expressed in osteocytes of
DMP1-null mice. Therefore, excess production of FGF23
in osteocytes seems to cause ARHR. However, it remains
unclear how mutations in DMP1 gene cause enhanced
production of FGF23.4 International Journal of Pediatric Endocrinology
Table 1: Causes of rickets/osteomalacia.
Genetic diseases
FGF23-related rickets Autosomal dominant hypophosphatemic rickets/osteomalacia
(mutations in FGF23 gene)
Autosomal recessive hypophosphatemic rickets/osteomalacia
(mutations in DMP1 gene)
X-linked hypophosphatemic rickets/osteomalacia
(mutations in PHEX gene)
McCune-Albright syndrome/Fibrous dysplasia
(somatic mutations in GNAS1 gene)
Deﬁcient action of 1,25(OH)2D Vitamin D-dependent rickets type 1
(mutations in CYP27B1 gene)
Vitamin D-dependent rickets type 2 (mutations in VDR gene)
Dysfunction of renal tubules Fanconi syndrome
Dent disease (mutations in CLCN5 gene)
Some renal tubular acidosis
Others Hereditary hypophosphatemic rickets/osteomalacia with hypercalcemia
(mutations in SLC34A3 gene)
Hypophosphatasia (mutations in TNALP gene)
Acquired diseases
FGF23-related rickets/osteomalacia Tumor-induced hypophosphatemic rickets/osteomalacia
Deﬁciency of vitamin D or phosphate Premature birth
Undernutrition
Vitamin D deﬁciency, shortage of daylight
Drug-induced rickets/osteomalacia Antiepileptic drugs, Saccharated ferric oxide (Iron polymaltose), Aluminum, and so forth
Others Chronic renal disease, and so forth
FGF23: ﬁbroblast growth factor 23; DMP1: dentin matrix protein 1; PHEX: phosphate-regulating gene with homologies to endopeptidases on the X
chromosome; VDR: vitamin D receptor; GNAS1: guanine nucleotide binding protein, alpha stimulating 1; TNALP: Tissue nonspeciﬁc alkaline phosphatase.
4.4.XLH. XLHisconsideredtobethemostfrequentcauseof
vitaminD-resistanthypophosphatemicrickets/osteomalacia.
T h ef r e q u e n c yo fX L Hi sr e p o r t e dt ob ea b o u t1i n2 00 0 0
births [25]. The responsible gene for XLH was identiﬁed in
1995 and named phosphate-regulating gene with homologies
to endopeptidases on the X chromosome (PHEX)[ 26]. The
expression of PHEX is found in osteocytes, osteoblasts, and
odontoblasts [27]. Although PHEX protein shows homology
to endopeptidases with single membrane-spanning region,
it is not clear whether PHEX physiologically works as an
endopeptidase. Hyp mouse, which has a deletion in 3
portion of Phex gene, is known as a model of XLH. Several
results suggest that hypophosphatemia in Hyp and XLH
patients is caused by some humoral factor. For example,
the crosstransplantaion of kidneys in wild-type and Hyp
mice did not change their phenotypes [28]. In addition,
renal transplantation from a healthy donor to a patient with
XLH did not correct renal phosphate wasting [29]. It has
been shown that serum FGF23 levels in most XLH patients
are above the reference range [30, 31]. Serum FGF23 levels
in Hyp mice are also elevated, and excess production of
FGF23 is found particularly in bone of Hyp mice. These
results indicate that the overexpression of FGF23 in bone
is responsible for hypophosphatemic rickets/osteomalacia in
patients with XLH and Hyp mice. Again, it remains to be
clariﬁed how PHEX protein regulates the synthesis of FGF23
in bone.
4.5. MAS/FD. FD is a bone lesion in which medullary cavity
is replaced by ﬁbrous, osseous, and chondral tissues. FD
occurs either as monostotic (70%–80%) or as polyostotic
(20%–30%) form. MAS is a syndrome consisting of polyos-
totic ﬁbrous dysplasia, skin hyperpigmentation (caf´ e-au-
lait spots), and endocrine dysfunction, frequently seen in
females as precocious puberty. MAS is caused by somatic
mosaicism ofcells harboring activating mutations in guanine
nucleotide binding protein, alpha stimulating 1 (GNAS1)
gene. These mutations are also observed in FD tissues
withoutMAS.Approximately50%ofMAS/FDpatientsshow
hypophosphatemicrickets/osteomalacia.Itwasreportedthat
FGF23 production is found in bone including regions of
FD, and circulatory FGF23 levels are increased in MAS/FD
patients who show hypophosphatemic rickets/osteomalacia
[3]. However, it is not demonstrated that enhanced cyclic
AMP level actually increases FGF23 production, and the
mechanismofFGF23overproductionremainstobeclariﬁed.
4.6. TIO. TIO is a paraneoplastic syndrome usually associ-
ated with mesenchymal slow-growing tumors. Most tumorsInternational Journal of Pediatric Endocrinology 5
responsible for TIO are now pathologically classiﬁed as
phosphaturic mesenchymal tumors, mixed connective tissue
variant (PMTMCT). FGF23 was identiﬁed as a causative
humoral factor for TIO, which is quite rare in childhood
[5]. FGF23 was shown to be abundantly expressed in tumors
causing TIO [5, 32]. Circulatory FGF23 levels are elevated in
virtually all patients with TIO [31]. The surgical removal of
responsible tumors results in normalization of FGF23 levels
and cures this disease.
5. HyperphosphatemicDiseases
Tumoral calcinosis is characterized by ectopic calciﬁcation
especially around large joints. While the commonest form
of tumoral calcinosis is observed in patients with end-
stage renal disease undergoing dialysis, there are hereditary
forms of tumoral calcinosis with normal renal function
[33, 34]. Familial hyperphosphatemic tumoral calcinosis is
a rare autosomal recessive disorder that is characterized by
enhanced renal tubular phosphate reabsorption and rather
high serum 1,25(OH)2D levels for hyperphosphatemia [34].
Biallelic mutations in GALNT3, FGF23, and Klotho
have been shown to cause this hyperphosphatemic disease
[35–38]. Mutations in GALNT3 and FGF23 have been
shown to cause susceptibility of FGF23 protein to the
processing between 179Arg and 180Ser resulting in low
levels of full-length FGF23. GALNT3 encodes a protein
called UDP-N-acetyl-alpha-D-galactosamine: polypeptide
N-acetylgalactosaminyltransferase 3. This is an enzyme
involved in the synthesis of mutin-type O-linked glycans.
Homozygous missense mutations in GALNT3 gene seem
to cause impaired glycosylation of FGF23 protein making
it susceptible for the processing. FGF23 mutations are
postulated to cause the susceptibility by changing protein
structure of FGF23. A homozygous mutation of Klotho has
been shown to make the expression of Klotho protein to be
markedly reduced, resulting in diminished ability of FGF23
protein to act on target organs [38].
FGF23 is marginally elevated in patients with hypo-
parathyroidism [39]. High level of FGF23 is also found in
patients with chronic kidney disease, especially in patients
with end-stage renal disease [40]. The high level of FGF23
in these diseases is regarded as a compensatory response to
hyperphosphatemia or phosphate overload. However, it is
stillpossiblethatsomeotherfactorsassociatedwithimpaired
renal function are contributing to the increase of FGF23
because FGF23 level is extremely high in some patients with
end-stage renal disease.
6. Conclusion
FGF23 was shown to be produced by bone and act on
kidney through a speciﬁc receptor system. In addition, excess
and deﬁcient actions of FGF23 result in hypophosphatemic
and hyperphosphatemic diseases, respectively. These results
indicate that FGF23 works as a hormone, and several disor-
ders of phosphate metabolism can be viewed as endocrine
diseases. However, there still remain several important
questions unanswered such as regulatory mechanisms of
FGF23 production and signals beyond Klotho-FGFR1c that
mediate FGF23 action. On the other hand, anti-FGF23 anti-
bodies were already shown to increase serum phosphate and
1,25(OH)2Dl e v e l sb o t hi nw i l d - t y p ea n dHyp mice [41, 42].
Like many other endocrine diseases, it may become possible
to treat patients with abnormal phosphate metabolism by
regulating the activity of this phosphotropic hormone.
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